Non-Small Cell Lung Cancer

Patients with early-stage non–small cell lung cancer had improved outcomes after surgical treatment if they adhered to quality metrics associated with survival.

In advanced non–small cell lung cancer (NSCLC), discontinuing immunotherapy after 2 years can maintain durable responses while reducing financial and toxicity burdens, with decisions guided by residual disease testing and shared decision-making, explained Jonathan Thompson, MD, MS.

Making treatment for non–small cell lung cancer (NSCLC) accessible to a wide range of the population can help to improve outcomes from and knowledge of the condition.

Precision oncology's promise was the key theme of the July 17 session of the Institute for Value-Based Medicine with faculty from multiple institutions in the Boston, Massachusetts area.

New drugs aren't the only advances in oncology. Innovation includes collaboration between to remove barriers to remove barriers to care, according to experts who gathered for a session of the Institute for Value-Based Medicine in Arlington, Virginia.

Cutting-edge cancer therapies and innovative care models that advance patient access and significantly reduce health care costs took center stage at the Institute of Value-Based Medicine (IVBM) event in Minneapolis, Minnesota.

Jonathan Thompson, MD, MS, explains that adjuvant immunotherapy benefits patients with early-stage lung cancer with incomplete neoadjuvant response, while treatment decisions in the adjuvant setting must weigh efficacy, toxicity, and limited evidence.

Jonathan Thompson, MD, MS, highlighted that reducing delays in molecular testing and treatment initiation is critical for improving lung cancer outcomes, and that clinical trial data suggest immunotherapy duration can often be safely de-escalated in patients who achieve a complete pathologic response.

A panel held during the Institute for Value-Based Medicine event in Chicago on August 14, 2025, included discussions of access to biomarker testing and perioperative treatment in patients with non–small cell lung cancer (NSCLC).

Jonathan Thompson, MD, MS, emphasized that broader molecular testing in early-stage non–small cell lung cancer (NSCLC) is essential to guide perioperative treatment decisions, while selective retesting at progression can identify resistance mutations or new targets to optimize value-based care.

Jonathan Thompson, MD, MS, emphasized that comprehensive biomarker testing with next-generation sequencing and PD-L1 analysis—implemented as reflex testing at biopsy—is essential to guide precision therapy in lung cancer and to address persistent disparities in timely, equitable access to care.

Selected patients with a clinical response after therapy could benefit from salvage surgery in non–small cell lung cancer (NSCLC), with acceptable results for perioperative morbidity.

The newly developed model has an area under the curve of 0.807 for predicting progression-free survival.

Zongertinib gains FDA approval for treating HER2-mutated non–small cell lung cancer (NSCLC), offering hope with fewer side effects and promising response rates in patients.

Bevacizumab combined with chemotherapy was not as effective in advanced driver gene-negative nonsquamous non–small cell lung cancer (NSCLC) compared with immune checkpoint inhibitors plus chemotherapy.

In this first part of an interview with The American Journal of Managed Care®, Julia Rotow, MD, thoracic oncologist at Dana-Farber Cancer Institute, discusses the critical need to test for biomarkers to afford patients the chance to benefit from recent treatment advances.

Seventy percent of Asian American and Pacific Islander women diagnosed with lung cancer were non- or never-smokers, highlighting a need to rethink lung cancer screening to reduce disparities.

There is a great need to streamline the process from the tissue sample to the diagnostic lab, whether it's genomic or immunohistochemistry, Robert Kratzke, MD, says.

Tabby Khan, MD, MPH, senior director of Analytics at Komodo Health, calls for increased lung cancer screening measures and criteria to address underreported, at-risk populations like AAPI women.

Robert Kratzke, MD, urged insurance providers to prioritize fast biomarker testing in non–small cell lung cancer, saying it’s both cost-effective and life-saving.

The hemoglobin, albumin, lymphocyte, and platelet (HALP) score can help to guide treatment decisions in patients living with non–small cell lung cancer (NSCLC).

New research reveals critical gaps in treatment for advanced non–small cell lung cancer (NSCLC), emphasizing the need for innovative therapies to improve patient outcomes.

The treatment marks the only targeted oral treatment in patients with non–small cell lung cancer with epidermal growth factor receptor exon 20 insertion mutations.

The COCOON trial reveals that prophylactic treatment reduces dermatological adverse events in NSCLC patients, enhancing their quality of life during amivantamab therapy.

Zongertinib shows promising results in HER2-mutant NSCLC, offering high response rates and improved quality of life with minimal toxicity.